DNA polymeraseη protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy

Table 1 Patient characteristics (N = 80)

characteristic	No. of patients	%
Age(yrs)
Median	54.0
Range	26.0-79.0
Sex
Male	49	61.3
Female	31	38.7
ECOG performance status
0	36	45.0
1	42	52.5
2	2	2.5
Primary sites
Cardia	21	26.3
Body	18	22.5
Antrum/pylorus	41	51.2
Metastatic sites
Liver	26	32.5
Lung	21	26.3
Peritoneum	19	23.8
Others	14	17.4
Pathologic differentiation N0
G1	2	2.5
G2	26	32.5
G3	52	65.0
Treatment Response (1st line)
CR	2	2.5
PR	36	45.0
SD	24	30.0
PD	18	22.5
2^nd-line chemotherary regimen
BSC	57	71.3
FOLFIRI	6	7.5
XELIRI	8	10.0
DX	6	7.5
TP	3	3.7

CR, complete response; PR, partial response; SD, stable disease; PD, progression disease;
BSC, best supportive care; FOLFIRI, 5-fluracil plus leucovorin plus irinotecan; XELIRI, capecitabine plus irinotecan; DX, docitaxel plus capecitabine; TP, paclitaxel plus cisplatin.

ISSN: 1479-5876